Agilent | Trusted AnswersAgilent | Trusted Answers

Agilent at ESHG 2024

June 1 - 4 | Germany, Berlin | Booth #648

Page Title | Agilent

Agilent Welcomes you at ESHG 2024

We are delighted to meet you at the 57th annual European Human Genetics Conference taking place in Berlin, Germany from June 1st to June 4th.

During this unique opportunity, Agilent displays new products and supports you to build your scientific projects. We will welcome you at Booth#648 where Agilent experts give you live demonstrations of the instruments and show you our solutions.

In addition, Agilent leads exclusive presentations by esteemed guests, spanning diverse subjects from genetic, and rare disease testing to cancer screening. Please continue reading for more details about each presentation.

Register for our Corporate Satellite

Live Demonstrations

Learn more About our Instruments

Discover the solution suited to your projects:

  • Fully automated NGS library prep system with Agilent Magnis NGS Prep System
  • NGS QC made easy with Agilent TapeStation Systems
  • Automated Microscopy and live cell assays with BioTek Cytation Cell Imaging Multimodel Reader
  • Whole exome sequencing with Exome V8
  • CGP with SureSelect Cancer
  • DNA and methylation in one target enrichment workflow with Avida
  • IVDR cytogenetic solutions with GenetiSure Dx Postnatal Assay
  • Automate your denatured protein analysis with the new Agilent ProteoAnalyzer System
Book a meeting with our team or guest speakers

Be Part of our Corporate Satellite

Title: Future Frontiers in Human Genetics: Discovering Emerging Genomic Solutions - Customer Success Stories

Date: Saturday 1st June, Room Helsinki 1

Time: 12:00 – 13:30 CEST (lunch will be provided)

Three exclusive presentations for the attendees.

Register today

Succeeding in Multiomics and Liquid Biopsy with Versatile Tools

Keynote Speaker - Markus Billeter, AVP, Agilent Technologies, USA 

The scope of laboratory workflows is expanding to encompass further insights, including methylation studies. With ongoing cost pressures, selecting the appropriate set of tools has never been more critical.
The choice depends on the type of sample, like tissue or liquid biopsies in oncology, and the specific objectives of the testing. This talk will shed some light and an update into the ever-growing genomics ecosystem.

Pushing the Boundaries: the Limit of Detection in NGS Liquid Biopsy

Guest Speaker - Dr. rer. nat. Denny Schanze, Institut für Humangenetik, Germany 

Beside WES and WGS analyses the need for special toolsets for mosaic detection and liquid biopsy is of high interest in special areas of research and clinical routine. The knowledge about mosaic disease is rapidly increasing. Over the last four years, we established toolsets for mosaic detection and liquid biopsy by evaluation and validation of different molecular barcoding technologies and library preparation methods including the Magnis NGS Prep System. We will provide details regarding the various steps in the validation process to select the optimum assay design for the highest sensitivity and precision at the desired limit of detection while keeping the assay cost-efficient for routine diagnostics.

Enhanced Identification of Disease-causing Genetic Variants Using a Human Comprehensive Focused Genome Sequencing

Guest Speaker - Cristina Cano Moratilla, Msc., Facultativo Departamento de Biología Molecular Eurofins Megalab, Spain

With the advent of genome sequencing, the detection of variants such as CNVs, repeat disorders, inversions, and deep intronic variants that required various laboratory techniques, has been improved.
However, not all laboratories can sequence a human genome.  Designing a whole exome panel plus clinically relevant genome content, it makes possible to improve the genome-wide mutation rate with the advantages of and ease of use of exome workflow.
In this work, we share our results of how the New Agilent Clinical Research Exome V4 (CREv4) leverages valuable insights and discoveries from whole-genome sequencing (WGS) using a new exome approach that bridges the gap between whole-exome sequencing (WES) and WGS, with unique features such as curated deep intronic sites, mini-genomes and Repeat disorders among others. CREv4 laboratory workflow is fully compatible with the Agilent Magnis NGS prep system for complete walkaway automation and a benchtop sequencer, consistently reducing turnaround time (TAT), compared to other platforms.

Meet our Speakers

Markus Billeter

Keynote Speaker - AVP, Agilent Technologies, USA 

Dr. rer. nat. Denny Schanze

Guest Speaker - Institut für Humangenetik, Germany 

Cristina Cano Moratilla, Msc.

Guest Speaker - Facultativo Departamento de Biología Molecular Eurofins Megalab, Spain

Agilent Partners at ESHG 2024

Partner with CiberMed on a Digital Cytometry Solution to Enable Cellular Profiling

Learn more

Add Proteomic Analysis to your Lab with the SomaScan®️ Platform from SomaLogic®️

Learn more

For Research Use Only. Not for use in diagnostic procedures.

PR7001-2464

Register for our Corporate Satellite or Book a Meeting with our Team

Add one question if they want to meet our team

Your Personal Data

* This field is required

Your Visit at ESHG 2024

Your Purchase Plan











For full details of how we will treat your information please view our privacy policy: www.agilent.com/home/privacy-policy
Partner with CiberMed on a Digital Cytometry Solution to Enable Cellular Profiling

Agilent is partnering with CiberMed to simplify cellular profiling and biomarker discovery with their digital cytometry software, iSort. CiberMed’s iSort digital cytometry solution enables highly accurate, cost-effective profiling of cell type composition and expression from total RNA extracted from bulk blood and solid tissue samples. This method for cytometry by sequencing overcomes the barriers of traditional cell profiling methods where throughput, cost, preservation state, number of cells, and/or sample dissociation may pose challenges. The utility of iSort has been demonstrated in multiple contexts, including immuno-oncology, biomarker discovery, organ transplantation, cardiology, autoimmune disease, development, aging, and sepsis. The core algorithm underlying iSort (CIBERSORT/x) is being used in clinical trials and has become the standard methodology for deconvolution in large cancer studies and datasets, such as The Cancer Genome Atlas (TCGA). It is one of the fastest-growing software tools in the life sciences.

Learn more
Add Proteomic Analysis to your Lab with the SomaScan®️ Platform from SomaLogic®️

We believe that collaboration drives progress. That's why Agilent partners with SomaLogic, whose SomaScan®️ Technology is a comprehensive solution for proteomic interrogation of up to 11,000 protein measurements in a single sample. The aptamer-based SomaScan®️ Assay provides a powerful solution that covers half of the genetically encoded human proteome and enables you to detect proteins across every major biological pathway. For over 10 years, SomaLogic has used the hybridization technology of the Agilent Microarray platform as its read-out, ensuring that the SomaScan Platform offers the largest protein content on the market, highly reproducible results (~5% coefficient of variation), a quick turnaround time, and easily scalable throughput. SomaLogic has conducted more than 3 billion protein measurements to date. The SomaScan Assay is available as a service through SomaLogic’s US-based CLIA-certified, CAP-accredited lab, and at a growing number of locations worldwide.

Learn more